New Approaches to Identifying Unfair Competition When Introducing Generic Drugs into Civil Circulation
In June 2024, the pharmaceutical industry faced a new practice by the Federal Antimonopoly Service (FAS), which began to consistently recognize the introduction of generic drugs onto the market as unfair competition.